Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40441 | 0.97 | ESR1 (0.70) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL11648324 | 0.97 | ESR1 (0.70) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL31123062 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL9356953 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL28460829 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL3962149 | 0.93 | ESR1 (0.75) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL31123063 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL2046588 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL11420354 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL28859132 | 0.93 | ESR1 (0.67) | ESR1ESR2TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678104-B1 | PROCESS FOR PRODUCING 1-OCTENE FROM BUTADIENE IN THE PRESENCE OF TITANIUM CATALYSTS | POLIMERI EUROPA SPA (IT) | 2010-02-17 | — | — | EP | disclosed |
| EP-1678103-B1 | PROCESS FOR THE PREPARATION OF 1-OCTENE | POLIMERI EUROPA SPA (IT) | 2009-06-03 | — | — | EP | disclosed |
| US-7368623-B2 | Process for producing 1-octene from butadiene in the presence of titanium catalysts | POLIMERI EUROPA S.P.A. (IT) | 2008-05-06 | — | — | US | disclosed |
| US-7368622-B2 | Two step process; bis-hydrodimerization of butadiene to 1,7-octadiene in presence of palladium catalyst containing one or more tri-substituted monodentate phosphines; catalytic hydrogenation using non-supported ruthenium complex in aprotic polar solvent of cyclic urea | POLIMERI EUROPA S.P.A. (IT) | 2008-05-06 | — | — | US | disclosed |
| US-20070179327-A1 | Process for producing 1-octene from butadiene in the presence of titanium catalysts | POLIMERI EUROPA S.P.A. (IT) | 2007-08-02 | — | — | US | disclosed |
| US-20070129585-A1 | Process for the preparation of 1-octene | POLIMIERI EUROPA S.P.A. (IT) | 2007-06-07 | — | — | US | disclosed |
| EP-1678104-A1 | PROCESS FOR PRODUCING 1-OCTENE FROM BUTADIENE IN THE PRESENCE OF TITANIUM CATALYSTS | Polimeri Europa S.p.A. (IT) | 2006-07-12 | — | — | EP | disclosed |
| EP-1678103-A1 | PROCESS FOR THE PREPARATION OF 1-OCTENE | Polimeri Europa S.r.l. (IT) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005047217-A1 | PROCESS FOR THE PREPARATION OF 1-OCTENE | POLIMERI EUROPA S.P.A. (IT) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047218-A1 | PROCESS FOR PRODUCING 1-OCTENE FROM BUTADIENE IN THE PRESENCE OF TITANIUM CATALYSTS | POLIMERI EUROPA S.P.A. (IT) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179327-A1 | Process for producing 1-octene from butadiene in the presence of titanium catalysts | CTNND1, BBOX1, TDO2 | ESR1 3692/4885ESR2 3562/4885TDP1 443/4885 |
| US-20070129585-A1 | Process for the preparation of 1-octene | PDCD2L, UPP1, NONO | ESR1 4717/4885ESR2 3670/4885TDP1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.